ArticleJournal of orthopaedic case reports2024
Transient Osteoporosis of Hip as a Part of "Long COVID-19": A Case Series.
Article in Journal of orthopaedic case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Transient osteoporosis of the hip (TOH) presents with symptoms such as groin pain, discomfort, and the presence of bone edema detected on magnetic resonance imaging (MRI) scans. We have observed an increase in the occurrence of TOH in patients following the COVID-19 pandemic. Case Report: In this series, we present four cases of TOH that developed after COVID-19 infection. The average cumulative dose of prednisolone exposure in these cases was 788 mg (range 300-1050 mg). The mean duration between diagnosis and COVID-19 infection was 102 days (range 90-123 days). The average duration from the resolution of symptoms to the initiation of bisphosphonate therapy was 98 days (range 90-120 days). Conclusion: Bisphosphonate therapy appears to be an effective pharmacological treatment for TOH, providing rapid pain relief and shortening the disease's natural course. This study demonstrates positive outcomes, including normalized MRI results and no progression to avascular necrosis, suggesting bisphosphonates as a promising management option for TOH patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.